Matriptase-2 Inhibitor Compounds for Hepcidin Regulation in IRIDA

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Matriptase-2 activity leads to inappropriate hepcidin production, causing iron-refractory iron deficiency anemia (IRIDA) due to mutations, which can be addressed by inhibiting the enzyme to regulate iron metabolism effectively.

Innovation Solution

Development of compounds that inhibit Matriptase-2 activity, specifically targeting its modular structure to increase hepcidin production and treat associated disorders.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If Matriptase-2 activity is increased, then hepcidin production is suppressed, but iron metabolism regulation is impaired causing IRIDA

Engineering Contradiction:

Improvehepcidin productionVSAvoidiron metabolism regulation

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent applies preliminary anti-action by developing compounds that preemptively inhibit Matriptase-2 enzyme activity before it can suppress hepcidin production. The compounds of Formula I are designed to bind to and inhibit the catalytic domain of Matriptase-2, preventing the harmful suppression of hepcidin and thereby maintaining proper iron metabolism regulation.

Inventive Principle:

Principle #9Preliminary anti-action

Solution Approach 2:

The patent uses small molecule compounds as intermediaries to modulate the interaction between Matriptase-2 and hepcidin. These compounds act as mediators that bind to the Matriptase-2 enzyme and prevent its suppressive effect on hepcidin production, thereby restoring proper iron metabolism without directly manipulating hepcidin levels.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Quantity of substance

If Matriptase-2 is inhibited, then hepcidin production increases, but enzyme activity suppression must be controlled

Engineering Contradiction:

Improvehepcidin productionVSAvoidenzyme activity control

Core Design Contradiction:

Quantity of substanceVSDevice complexity

Solution Approach 1:

The patent applies parameter changes by modifying the chemical structure of compounds (Formula I with various R1, R2, R3 substituents) to optimize their inhibitory potency and selectivity toward Matriptase-2. By changing molecular parameters such as substituent groups and molecular weight, the compounds achieve controlled inhibition of the enzyme while promoting appropriate hepcidin production levels.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS12428415B2Matriptase 2 inhibitors and uses thereof

Publication Date: 2025.09.30 DISC MEDICINE INC

AI summary

The present invention provides compounds for inhibiting matriptase 2, or a mutant thereof, and compositions and methods of use thereof.